Stribild is a fixed-dose tablet combining 150mg elvitegravir, 200mg emtricitabine, and 245mg tenofovir disoproxil, along with 150mg cobicistat, a boosting agent. It is manufactured by Gilead Sciences.

Elvitegravir is an integrase inhibitor, emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI). These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses.

The standard dose of Stribild is one green tablet, once a day, taken with food.

Stribild was licensed in the United States in August 2012 and approved for use in the European Union in May 2013.

For more information on Stribild's component drugs, including drug interactions, side-effects and resistance, see elvitegravir (Vitekta), emtricitabine, Emtriva and tenofovir (Viread).